Synch has advised Claret Capital Partners on its investment of up to €28 million in Cinclus Pharma Holding AB (publ).
Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases. The investment from Claret Capital Partners will enable an earlier start of the final stage of Cinclus Pharma’s Phase III clinical program and support the remaining development and pre-launch activities of its lead asset, linaprazan glurate, towards market approval and commercialisation.
With this investment, Claret continues to support late-stage biotech innovation, contributing to the development of a potential best-in-class therapy for patients. Claret is one of Europe’s leading independent growth debt fund managers, and this transaction represents a further expansion of its Life Sciences portfolio.
"Synch were a highly effective legal partner on the Cinclus Pharma transaction, providing clear, pragmatic advice and strong execution throughout the process. We were delighted to work with them again on this investment; the team demonstrated deep technical expertise and sound judgement, supporting a smooth execution from start to finish." - Philip Treacy, Vice President at Claret Capital Partners
This investment is one of several life sciences transactions completed by Claret through Fund IV in recent months, highlighting the strength of opportunities within the European healthcare and life sciences sector. Claret has a strong track record across the life sciences spectrum, from medtech and therapeutics to services and digital health, supporting founders and their venture capital partners while minimising dilution and maximising shareholder value.
Synch's venture debt financing team was led by Andreas Börjesson, Sofia Tångelin and Johan Hedlund.
